TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28723831
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 10.0 mg
Study: 28723831
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 7.5 mg or higher
Study: 14562564
Drug: Prophylactic antifibrinolytic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antifibrinolytic therapy
Study: 16897906
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy
Study: 11581553
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) at a dose of 3.5 mg/kg body weight administered by deep intramuscular injection once a week for 12 weeks
Study: 3086177
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg)
Study: 26259134
Drug: GH 1
Normalized name: Cough 100mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 1 mg/m(2) per day with GnRHa
Study: 26259134
Drug: GH 2
Normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 2 mg/m(2) per day with GnRHa
Study: 26259134
Drug: GH 1
Normalized name: Cough 100mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 1 mg/m(2) per day
Study: 26259134
Drug: GH 2
Normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 2 mg/m(2) per day
Study: 22071701
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (2 mg/kg daily)
Study: 22071701
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (1 mg/kg daily)
Study: 22071701
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/kg daily)
Study: 30699415
Drug: Enarodustat 2
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Enarodustat 2 mg, 4 mg, or 6 mg once daily for 6 weeks (Period 1) followed by 24 weeks of open enarodustat treatment (Period 2)
Study: 30699415
Drug: Enarodustat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enarodustat (various doses)
Study: 8441107
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline therapy
Study: 3535158
Drug: Aspirin (high-dose)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (high-dose)
Study: 14984383
Drug: Aspirin (low-dose)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (low-dose)
Study: 3535158
Drug: Heparin-Dihydroergotamine (heparin-DHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-Dihydroergotamine (heparin-DHE)
Study: 18794104
Drug: Intravenous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous IL-2 (18 x 10(6) IU/m(2)/d) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Study: 18794104
Drug: Subcutaneous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-2 (9 x 10(6) or 18 x 10(6) IU) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Study: 18794104
Drug: Intravenous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous IL-2
Study: 18794104
Drug: Subcutaneous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-2
Study: 12505245
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/d)
Study: 26704170
Drug: Other nonstandard
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other nonstandard therapies
Study: 25182696
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a biologic drug based on NICE guidelines
Study: 25182696
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice for switching biologic drugs
Study: 25182696
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of a biologic drug due to lack of effect
Study: 1783248
Drug: Lactitol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (20 g)
Study: 1783248
Drug: Maltitol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol (20 g)
Study: 1975490
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine sulfate
Study: 1542838
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) morphine sulfate
Study: 7437259
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin (diamorphine) 2.5 mg and 5 mg for non-dependent; 1/6, 1/3, and 1/2 of prescribed daily dose for dependent subjects
Study: 25934175
Drug: Interpersonal Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Community Psychiatric Treatment (ICPT)
Study: 28800895
Drug: WeCareAdvisor™ (immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: WeCareAdvisor™ (immediate treatment group)
Study: 28800895
Drug: WeCareAdvisor™ (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: WeCareAdvisor™ (delayed treatment group)
Study: 21235696
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg q.d. monotherapy
Study: 19491283
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² on week 1 followed by 250 mg/m² weekly)
Study: 17218374
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 15 mg
Study: 16676098
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 100 mg/day for one month
Study: 11182175
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg once daily
Study: 7848024
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily
Study: 7740012
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of classroom and television delivery
Study: 2405349
Drug: Aztreonam, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam, 150 mg/kg/day intravenously
Study: 23485845
Drug: Thrust and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrust and nonthrust manipulation and exercise with myofascial therapy
Study: 23485845
Drug: Thrust and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrust and nonthrust manipulation and exercise without myofascial therapy
Study: 20806430
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (sulfasalazine 2400 mg/d with probiotic)
Study: 20806430
Drug: Sulfasalazine group
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine group (sulfasalazine 2400 mg/d)
Study: 18821688
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg from baseline through week 96, administered every 6 weeks after a loading dose
Study: 18821688
Drug: Placebo through
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo through week 24 and then infliximab 5 mg/kg from week 24 through week 96
Study: 18821688
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control cohort from OASIS database (no prior use of anti-TNF agents)
Study: 12461760
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release melatonin 6 mg
Study: 8554944
Drug: Selegiline (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (four doses of 10 mg over the preceding 3 days)
Study: 1710660
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of gamma globulin (IVGG) plus aspirin
Study: 31131679
Drug: Active SBCM
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active SBCM (treatment)
Study: 17362495
Drug: Conventional two-stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional two-stage restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed after 26 weeks, and definitive crowns placed 8 weeks later
Study: 8348391
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg bid
Study: 11895463
Drug: No intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intracoronary treatment (group 1)
Study: 17696673
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment conditions
Study: 14621851
Drug: Monoclonal T‐cell‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal T‐cell‐specific antibodies (OKT3) for 7 days (n = 27)
Study: 24199581
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride
Study: 31574106
Drug: Control sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sessions (conventional therapy)
Study: 25348544
Drug: 1 implant
Normalized name: LEUPROLIDE ACETATE 72 MILLIGRAM In 1 IMPLANT SUBCUTANEOUS IMPLANT [Viadur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 implant in the midline (group 1)
Study: 25348544
Drug: 2 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants in the canine areas (group 2)
Study: 15172654
Drug: i.v. ibutilide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ibutilide treatment, up to 2 mg
Study: 8737553
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine (0.5ml/kg body weight of 0.25% solution)
Study: 3297570
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ampicillin (1 g X 3) and metronidazole (0.5 g X 3)
Study: 3297570
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of metronidazole and ampicillin
Study: 28589493
Drug: Omarigliptin 25
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 25 mg once weekly
Study: 9631989
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once weekly
Study: 28923291
Drug: Prohibited medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prohibited medication (metformin)
Study: 19593171
Drug: Flumazenil (FMZ)
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil (FMZ) 2 mg incremental bolus for 20 minutes for 2 consecutive days and Gabapentin (GBP) up to 1200 mg nightly for 39 days
Study: 17203620
Drug: Antidepressants prescribed
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants prescribed at effective doses
Study: 11125428
Drug: ISP- (isolated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISP- (isolated soy protein beverage providing 2.1 mg. of genistein and 1.3 mg. of daidzein daily)
Study: 16649828
Drug: Atomoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (10 weeks treatment)
Study: 16649828
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 weeks treatment)
Study: 31850360
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group
Study: 19723128
Drug: 1% voriconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% voriconazole eye drops, hourly for four doses
Study: 1163927
Drug: New topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New topical ophthalmic delivery systems (specific systems not detailed)
Study: 1163927
Drug: New topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New topical ophthalmic delivery systems
Study: 26237623
Drug: PPIA preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPIA preparation
Study: 22646659
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message intervention (N = 8)
Study: 22646659
Drug: Weekly general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly general health messages (N = 10)
Study: 21069290
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil (low, medium, and high doses)
Study: 20019427
Drug: Experimental bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental bonding agents containing calcium phosphates
Study: 16455838
Drug: Salbutamol pressurised
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol pressurised metered-dose inhaler 1,600 microg (metered)
Study: 8842656
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine hydrochloride 0.3 mg kg‐1 (n = 21)
Study: 7208540
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg clonidine sustained-release capsule, single oral dose, administered for 3 consecutive days
Study: 18824662
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Vitamin D3 (1000 mg of elemental calcium plus 400 IU of vitamin D3 daily)
Study: 16080281
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg tablets
Study: 12457629
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg daily azithromycin
Study: 12457629
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg daily azithromycin
Study: 10370876
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with red wine supplementation (240 ml/day)
Study: 1466214
Drug: Scopolamine 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.24 mg plus morphine 8 mg (Group 2)
Study: 1466214
Drug: Atropine 0.5
Normalized name: homatropine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.5 mg plus pethidine 50 mg (Group 1)
Study: 6700284
Drug: Short-term group
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term group therapy (15 weekly sessions)
Study: 6700284
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list (no immediate treatment)
Study: 23415202
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic treatment
Study: 21306419
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg scopolamine administered i.v.
Study: 15070921
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (1 mg daily) with cyclic micronized progesterone (200 mg for 10 days/month)
Study: 15070921
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol with cyclic micronized progesterone
Study: 11286153
Drug: Statins (lipid-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (lipid-modifying therapy)
Study: 24440672
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg once daily)
Study: 24440672
Drug: Mesalamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (3 g once daily)
Study: 18375270
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine at 2 mL/hr
Study: 18375270
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine at 5 mL/hr
Study: 10921699
Drug: GIK (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (500 mL D5W + 80 U regular insulin + 40 mEq KCl at 30 mL/hour)
Study: 10921699
Drug: No-GIK (D5W
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-GIK (D5W at 30 mL/hour)
Study: 1610422
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine
Study: 3518290
Drug: Ambroxol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 1,000 mg in 500 ml 5% glucose infusion i.v. daily from day 1 to day 5 and 2 ml placebo‐injection i.m. on day 1 and day 2
Study: 23094120
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) treatment
Study: 23696633
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) plus naproxen (NPX) 1000 mg daily
Study: 23696633
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) plus naproxen (NPX) 1000 mg daily
Study: 15277618
Drug: frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: frovatriptan 2.5 mg QD
Study: 10945314
Drug: Methoxsalen 10
Normalized name: methoxsalen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxsalen 10 mg plus nicotine 4 mg
Study: 10945314
Drug: Methoxsalen 30
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxsalen 30 mg plus nicotine 4 mg
Study: 10945314
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nicotine 4 mg
Study: 29443653
Drug: No Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Chemotherapy (no CT)
Study: 24887252
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine 0.25% at 1 ml/kg and neostigmine 1.5 ug/kg
Study: 24887252
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine 0.25% at 1 ml/kg
Study: 20378840
Drug: 28 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g/day textured soy flour (containing 14 g of soy protein) for 8 weeks
Study: 15703206
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (375 mg/day, titrated up to 2250 mg)
Study: 8942593
Drug: Intramuscular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tenoxicam 7.5 mg (IM group)
Study: 1822480
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention program including four 1 1/2 hour classes held at weekly intervals, selected maternal‐fetal interactive activities, recording of fetal movements, and maintaining of maternal diaries
Study: 24407163
Drug: Broad keywords
Normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad keywords (e.g., pregnancy)
Study: 11783602
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of blood pressure using ACE inhibitors, beta blockers, calcium antagonists, and/or thiazides.
Study: 9408691
Drug: Urodilatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin at a dose of 20 ng/kg/min for 7 days
Study: 14612478
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 7 days
Study: 3595071
Drug: Anirolac, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anirolac, 100 mg
Study: 3595071
Drug: Anirolac, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anirolac, 50 mg
Study: 3595071
Drug: Naproxen, 550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 550 mg
Study: 3595071
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active agents (Anirolac 50 mg, Anirolac 100 mg, Naproxen 550 mg)
Study: 31629852
Drug: CoQ10 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (400 mg per day)
Study: 23890931
Drug: Diuretic (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide 25 mg)
Study: 23890931
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or calcium channel blocker
Study: 23890931
Drug: Uncontrolled RH
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrolled RH treatment
Study: 21940597
Drug: HAMSB40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAMSB40 (40 g cooked high‐amylose maize starch with 31.8 mmol esterified butyrate)
Study: 21940597
Drug: HAMSB20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAMSB20 (20 g cooked high‐amylose maize starch with 31.8 mmol esterified butyrate)
Study: 30074128
Drug: Prasugrel 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 3.75 mg/day
Study: 31769845
Drug: Enteric-coated Mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated Mycophenolate Sodium (EC-MPS) plus low-dose prednisolone (0.25 mg/kg/day)
Study: 31769845
Drug: Standard-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prednisolone (1 mg/kg/day)
Study: 23211356
Drug: Continued dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued dual antiplatelet therapy (DAPT)
Study: 23211356
Drug: No continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: No continued dual antiplatelet therapy (DAPT)
Study: 19403844
Drug: Positive estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive estrogen receptor status
Study: 9303286
Drug: Subcutaneous ring
Normalized name: RING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ring block